NONOF (Novo Nordisk AS) Common Stock : $63 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Novo Nordisk AS Common Stock?

Novo Nordisk AS's quarterly common stock increased from Jun. 2024 ($64 Mil) to Sep. 2024 ($66 Mil) but then declined from Sep. 2024 ($66 Mil) to Dec. 2024 ($63 Mil).

Novo Nordisk AS's annual common stock increased from Dec. 2022 ($65 Mil) to Dec. 2023 ($66 Mil) but then declined from Dec. 2023 ($66 Mil) to Dec. 2024 ($63 Mil).

Novo Nordisk AS Common Stock Historical Data

The historical data trend for Novo Nordisk AS's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Common Stock Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

76.86

70.20

64.93

65.99

62.62

Novo Nordisk AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															65.99	65.75	64.32	66.39	62.62

Novo Nordisk AS Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (OTCPK:NONOF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.